All Stories

  1. Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience

    Article • Journal of Psychopharmacology, January 2026, SAGE Publications

    James Rucker

  2. Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment

    Article • EClinicalMedicine, December 2025, Elsevier

    James Rucker

  3. Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study

    Article • Acta Neuropsychiatrica, November 2025, Cambridge University Press

    James Rucker

  4. UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Complex Regional Pain Syndrome

    Article • Brain and Behavior, September 2025, Wiley

    James Rucker

  5. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial

    Article • Journal of Psychopharmacology, August 2025, SAGE Publications

    James Rucker

  6. UK Medical Cannabis Registry: A Clinical Analysis of Patients with Substance Use Disorder

    Article • European Addiction Research, July 2025, Karger Publishers

    James Rucker

  7. Characterising the clinical associations of hallucinogen persisting perceptual disorder: a retrospective cohort study

    Article • July 2025, Springer Science + Business Media

    James Rucker

  8. Corrigendum to “Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis” [Journal of affective disorders, 322 (2023), 194-204]

    Article • Journal of Affective Disorders, July 2025, Elsevier

    James Rucker

  9. Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review

    Article • Journal of Psychopharmacology, June 2025, SAGE Publications

    James Rucker

  10. Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework

    Article • Therapeutic Advances in Psychopharmacology, June 2025, SAGE Publications

    James Rucker

  11. An international Delphi consensus for reporting of setting in psychedelic clinical trials

    Article • Nature Medicine, June 2025, Springer Science + Business Media

    James Rucker

  12. Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial

    Article • Health Technology Assessment, May 2025, National Institute for Health Research

    Dr Kimberley Goldsmith, James Rucker

  13. UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder

    Article • Expert Review of Neurotherapeutics, April 2025, Taylor & Francis

    James Rucker

  14. Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK

    Article • The Lancet Psychiatry, April 2025, Elsevier

    Dr Kimberley Goldsmith, James Rucker

  15. UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy

    Article • Brain and Behavior, April 2025, Wiley

    James Rucker

  16. UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility‐Associated Chronic Pain

    Article • ACR Open Rheumatology, March 2025, Wiley

    James Rucker

  17. Participants’ Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis

    Article • Psychedelic Medicine, February 2025, SAGE Publications

    James Rucker

  18. UK Medical Cannabis Registry: An Analysis of Clinical Outcomes of Medicinal Cannabis Therapy for Cancer Pain

    Article • Journal of Pain & Palliative Care Pharmacotherapy, February 2025, Taylor & Francis

    James Rucker

  19. Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

    Article • Addiction, January 2025, Wiley

    James Rucker

  20. Psychedelic-related deaths in England, Wales and Northern Ireland (1997–2022)

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 2025, Elsevier

    James Rucker

  21. UK medical cannabis registry: an updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease

    Article • Expert Review of Gastroenterology & Hepatology, December 2024, Taylor & Francis

    James Rucker

  22. UK medical cannabis registry: A clinical outcome analysis of medical cannabis therapy in chronic pain patients with and without co‐morbid sleep impairment

    Article • Pain Practice, November 2024, Wiley

    James Rucker

  23. UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder

    Article • Expert Review of Neurotherapeutics, November 2024, Taylor & Francis

    James Rucker

  24. Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports

    Article • Psychological Medicine, November 2024, Cambridge University Press

    James Rucker

  25. Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

    Article • British Journal of Pharmacology, October 2024, Wiley

    James Rucker

  26. Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study

    Article • Journal of Pain & Palliative Care Pharmacotherapy, October 2024, Taylor & Francis

    James Rucker

  27. Plain Language Summary Publication: Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: Results from an open‐label phase Ib ascending dose study

    Article • Headache The Journal of Head and Face Pain, October 2024, Wiley

    James Rucker

  28. Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: results from an open‐label phase Ib ascending dose study

    Article • Headache The Journal of Head and Face Pain, September 2024, Wiley

    James Rucker

  29. Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol

    Article • Wellcome Open Research, July 2024, Faculty of 1000, Ltd.

    James Rucker

  30. Psilocybin and Motor Function: A Triple‐Blind, Dose‐Finding Study in Healthy Participants

    Article • Psychiatric Research and Clinical Practice, July 2024, American Psychiatric Association

    James Rucker

  31. Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry

    Article • International Clinical Psychopharmacology, July 2024, Wolters Kluwer Health

    James Rucker

  32. A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials

    Article • npj Mental Health Research, July 2024, Springer Science + Business Media

    James Rucker

  33. Clinical outcome analysis of patients with multiple sclerosis – Analysis from the UK Medical Cannabis Registry

    Article • Multiple Sclerosis and Related Disorders, July 2024, Elsevier

    James Rucker

  34. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases

    Article • Pharmacology & Therapeutics, June 2024, Elsevier

    James Rucker

  35. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants

    Article • Journal of Psychopharmacology, April 2024, SAGE Publications

    James Rucker

  36. Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry

    Article • Journal of Pain & Palliative Care Pharmacotherapy, April 2024, Taylor & Francis

    James Rucker

  37. UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study

    Article • BMJ Open, March 2024, BMJ

    James Rucker

  38. Corrigendum to “Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis”. [J. Affect. Disord., 322 (2023), 194–204]

    Article • Journal of Affective Disorders, March 2024, Elsevier

    James Rucker

  39. UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients

    Article • International Clinical Psychopharmacology, February 2024, Wolters Kluwer Health

    James Rucker

  40. UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia

    Article • Brain and Behavior, February 2024, Wiley

    James Rucker

  41. Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions

    Article • Neuropsychiatric Disease and Treatment, January 2024, Taylor & Francis

    James Rucker

  42. A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance

    Article • Neuropsychopharmacology Reports, December 2023, Wiley

    James Rucker

  43. UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study

    Article • December 2023, openRxiv

    James Rucker

  44. An observational study of clinical outcome measures in patients treated with cannabis‐based medicinal products on the UK Medical Cannabis Registry

    Article • Neuropsychopharmacology Reports, December 2023, Wiley

    James Rucker

  45. UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention‐deficit/hyperactivity disorder

    Article • Neuropsychopharmacology Reports, December 2023, Wiley

    James Rucker

  46. Corrigendum: Ceremonial ayahuasca in amazonian retreats—mental health and epigenetic outcomes from a six-month naturalistic study

    Article • Frontiers in Psychiatry, October 2023, Frontiers

    James Rucker

  47. Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis

    Article • Neuropsychiatric Disease and Treatment, October 2023, Taylor & Francis

    James Rucker

  48. An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part One

    Article • Psychiatric Annals, August 2023, SLACK, Inc.

    James Rucker

  49. On Redescribing the Indescribable: Trauma, Psychoanalysis and Psychedelic Therapy

    Article • British Journal of Psychotherapy, June 2023, Wiley

    James Rucker

  50. The development of psilocybin therapy for treatment-resistant depression: an update

    Article • BJPsych Bulletin, June 2023, Royal College of Psychiatrists

    James Rucker

  51. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression

    Article • Molecular Psychiatry, June 2023, Springer Science + Business Media

    James Rucker

  52. Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry

    Article • Psychopharmacology, June 2023, Springer Science + Business Media

    James Rucker

  53. Evidence versus expectancy: the development of psilocybin therapy

    Article • BJPsych Bulletin, May 2023, Royal College of Psychiatrists

    James Rucker

  54. Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry

    Article • Brain and Behavior, May 2023, Wiley

    James Rucker

  55. Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry

    Article • Expert Review of Neurotherapeutics, April 2023, Taylor & Francis

    James Rucker

  56. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

    Article • Journal of Affective Disorders, April 2023, Elsevier

    Scott Aaronson, James Rucker

  57. RE: Proposed Assisted Dying Bill: implications for mental healthcare and psychiatrists

    Article • The British Journal of Psychiatry, March 2023, Royal College of Psychiatrists

    James Rucker

  58. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

    Article • Journal of Psychopharmacology, March 2023, SAGE Publications

    Dr Kim P. C. Kuypers, James Rucker

  59. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry

    Article • Expert Review of Clinical Pharmacology, March 2023, Taylor & Francis

    James Rucker

  60. Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study

    Article • Expert Review of Neurotherapeutics, February 2023, Taylor & Francis

    James Rucker

  61. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

    Article • Journal of Affective Disorders, February 2023, Elsevier

    James Rucker

  62. Psilocybin therapy for depression. A good trip?

    Article • Journal of Mental Health, January 2023, Taylor & Francis

    James Rucker

  63. UK medical cannabis registry: assessment of clinical outcomes in patients with headache disorders

    Article • Expert Review of Neurotherapeutics, January 2023, Taylor & Francis

    James Rucker

  64. Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results

    Article • Journal of Neuropsychiatry, January 2023, American Psychiatric Association

    James Rucker

  65. Psilocybin for Dementia Prevention: Could Treating Major Depression with Psilocybin Alter the Neurodegenerative Disease Trajectory?

    Article • January 2023, Elsevier

    James Rucker

  66. The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry

    Article • Expert Review of Gastroenterology & Hepatology, December 2022, Taylor & Francis

    James Rucker

  67. Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy—Analysis from the UK Medical Cannabis Registry

    Article • Neuropediatrics, December 2022, Thieme Publishing Group

    James Rucker

  68. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2022, New England Journal of Medicine (NEJM/MMS)

    Scott Aaronson, James Rucker

  69. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry

    Article • Expert Review of Neurotherapeutics, November 2022, Taylor & Francis

    James Rucker

  70. Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry

    Article • Expert Review of Neurotherapeutics, November 2022, Taylor & Francis

    James Rucker

  71. Expectancy in placebo-controlled trials of psychedelics: if so, so what?

    Article • Psychopharmacology, September 2022, Springer Science + Business Media

    James Rucker

  72. Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review

    Article • Frontiers in Psychiatry, July 2022, Frontiers

    James Rucker

  73. Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)

    Article • Journal of Psychopharmacology, June 2022, SAGE Publications

    James Rucker

  74. Postpartum depression: A role for psychedelics?

    Article • Journal of Psychopharmacology, May 2022, SAGE Publications

    James Rucker

  75. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

    Article • Journal of Psychopharmacology, April 2022, SAGE Publications

    James Rucker

  76. An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry

    Article • Cannabis and Cannabinoid Research, January 2022, Mary Ann Liebert Inc

    James Rucker

  77. UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder

    Article • Expert Review of Clinical Pharmacology, January 2022, Taylor & Francis

    James Rucker

  78. UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes

    Article • Journal of Cannabis Research, January 2022, Springer Science + Business Media

    James Rucker

  79. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation

    Article • Journal of Psychopharmacology, January 2022, SAGE Publications

    James Rucker

  80. Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry

    Article • Therapeutic Advances in Psychopharmacology, January 2022, SAGE Publications

    James Rucker

  81. UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions

    Article • Expert Review of Clinical Pharmacology, December 2021, Taylor & Francis

    James Rucker

  82. Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

    Article • BMJ Open, December 2021, BMJ

    James Rucker

  83. A narrative synthesis of research with 5-MeO-DMT

    Article • Journal of Psychopharmacology, October 2021, SAGE Publications

    James Rucker

  84. Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis‐Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry

    Article • The Journal of Clinical Pharmacology, October 2021, Wiley

    James Rucker

  85. International online survey of 1048 individuals with functional neurological disorder

    Article • European Journal of Neurology, August 2021, Wiley

    James Rucker

  86. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study

    Article • CNS Drugs, July 2021, Springer Science + Business Media

    James Rucker

  87. Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

    Article • Frontiers in Psychiatry, June 2021, Frontiers

    James Rucker

  88. An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients

    Article • Neuropsychopharmacology Reports, May 2021, Wiley

    James Rucker

  89. Psilocybin: From Serendipity to Credibility?

    Article • Frontiers in Psychiatry, April 2021, Frontiers

    James Rucker

  90. Psilocybin and MDMA for the treatment of trauma-related psychopathology

    Article • International Review of Psychiatry, April 2021, Taylor & Francis

    James Rucker

  91. Psychedelics: Old drugs, new trips

    Article • Journal of Psychopharmacology, April 2021, SAGE Publications

    James Rucker

  92. A comparison of mdma-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis

    Article • European Psychiatry, April 2021, Royal College of Psychiatrists

    James Rucker

  93. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

    Article • Translational Psychiatry, March 2021, Springer Science + Business Media

    James Rucker, Greig de Zubicaray

  94. Effects of copy number variations on brain structure and risk for psychiatric illness: Large‐scale studies from the ENIGMA working groups on CNVs

    Article • Human Brain Mapping, February 2021, Wiley

    James Rucker

  95. 1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans

    Article • January 2021, Center for Open Science

    James Rucker

  96. Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA Working Groups on CNVs

    Article • January 2021, Center for Open Science

    James Rucker

  97. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis

    Article • Journal of Psychopharmacology, December 2020, SAGE Publications

    James Rucker

  98. 20 International online survey of 1162 individuals with functional neurological disorder: demographics, symptom comorbidities, self- management strategies, and illness beliefs

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 2020, BMJ

    James Rucker

  99. 21 Psychedelic treatment of functional neurological disorder – a systematic review

    Article • Journal of Neurology Neurosurgery & Psychiatry, July 2020, BMJ

    James Rucker

  100. Historic psychedelic drug trials and the treatment of anxiety disorders

    Article • Depression and Anxiety, July 2020, Wiley

    James Rucker

  101. Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition

    Article • JAMA Psychiatry, April 2020, American Medical Association (AMA)

    James Rucker, Greig de Zubicaray

  102. Psychedelic treatment of functional neurological disorder: a systematic review

    Article • Therapeutic Advances in Psychopharmacology, January 2020, SAGE Publications

    James Rucker

  103. Genome-wide Burden of Rare Short Deletions Is Enriched in Major Depressive Disorder in Four Cohorts

    Article • Biological Psychiatry, June 2019, Elsevier

    James Rucker

  104. Correction: Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia

    Article • Molecular Psychiatry, January 2019, Springer Science + Business Media

    James Rucker, Greig de Zubicaray

  105. Psychiatry & the psychedelic drugs. Past, present & future

    Article • Neuropharmacology, November 2018, Elsevier

    James Rucker

  106. Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia

    Article • Molecular Psychiatry, October 2018, Springer Science + Business Media

    James Rucker, Greig de Zubicaray

  107. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

    Article • Psychopharmacology, November 2017, Springer Science + Business Media

    James Rucker

  108. Interaction between the FTO gene, body mass index and depression: meta-analysis of 13701 individuals

    Article • The British Journal of Psychiatry, August 2017, Cambridge University Press

    James Rucker

  109. Psychedelics in the treatment of unipolar mood disorders: a systematic review

    Article • Journal of Psychopharmacology, November 2016, SAGE Publications

    James Rucker

  110. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

    Article • The Lancet Psychiatry, July 2016, Elsevier

    James Rucker

  111. Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder

    Article • Biological Psychiatry, February 2016, Elsevier

    James Rucker

  112. A comparison of mental state examination documentation by junior clinicians in electronic health records before and after the introduction of a semi-structured assessment template (OPCRIT+)

    Article • International Journal of Medical Informatics, September 2015, Elsevier

    Matthew Hotopf, James Rucker

  113. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential

    Article • BMJ, May 2015, BMJ

    James Rucker

  114. Chipping away at major depressive disorder

    Article • July 2014, Springer Science + Business Media

    James Rucker

  115. Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes

    Article • American Journal of Medical Genetics Part B Neuropsychiatric Genetics, April 2014, Wiley

    James Rucker

  116. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder

    Article • The Pharmacogenomics Journal, January 2014, Springer Science + Business Media

    James Rucker

  117. Correction: Harnessing Clinical Psychiatric Data with an Electronic Assessment Tool (OPCRIT+): The Utility of Symptom Dimensions

    Article • PLOS One, September 2013, PLOS

    Matthew Hotopf, James Rucker

  118. A review of the reliability and validity of OPCRIT in relation to its use for the routine clinical assessment of mental health patients

    Article • International Journal of Methods in Psychiatric Research, May 2013, Wiley

    James Rucker

  119. Male-Biased Autosomal Effect of 16p13.11 Copy Number Variation in Neurodevelopmental Disorders

    Article • PLOS One, April 2013, PLOS

    James Rucker

  120. Harnessing Clinical Psychiatric Data with an Electronic Assessment Tool (OPCRIT+): The Utility of Symptom Dimensions

    Article • PLOS One, March 2013, PLOS

    Matthew Hotopf, David O'Flynn, James Rucker

  121. Genomic structural variation in psychiatric disorders

    Article • Development and Psychopathology, October 2012, Cambridge University Press

    James Rucker

  122. Genome-wide association analysis of copy number variation in recurrent depressive disorder

    Article • Molecular Psychiatry, November 2011, Springer Science + Business Media

    James Rucker

  123. OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings

    Article • The British Journal of Psychiatry, August 2011, Royal College of Psychiatrists

    James Rucker

  124. Depressive disorder moderates the effect of the FTO gene on body mass index

    Article • Molecular Psychiatry, April 2011, Springer Science + Business Media

    James Rucker

  125. Polygenic Heterogeneity: A Complex Model of Genetic Inheritance in Psychiatric Disorders

    Article • Biological Psychiatry, August 2010, Elsevier

    James Rucker

  126. Mental capacity and psychiatric in-patients: implications for the new mental health law in England and Wales

    Article • The British Journal of Psychiatry, August 2009, Royal College of Psychiatrists

    James Rucker

  127. A Case of Prolonged Seizure After ECT in a Patient Treated With Clomipramine, Lithium, L-Tryptophan, Quetiapine, and Thyroxine for Major Depression

    Article • Journal of Ect, December 2008, Wolters Kluwer Health

    James Rucker

  128. Why do we need to understand the molecular basis of depression?

    Article • Biomarkers in Medicine, April 2008, Future Medicine

    James Rucker

  129. Article • Journal of Critical Care, June 2005, Elsevier

    James Rucker